Dianthus (NASDAQ: DNTH) EVP sells 33,830 shares after option exercise
Rhea-AI Filing Summary
Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa exercised stock options for 33,830 shares of common stock and sold 33,830 shares in an open-market transaction. The sale was executed at a price of $81.48 per share and made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following these transactions, Randhawa held no shares of common stock directly, according to the filing.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 33,830 shares ($2.14M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Randhawa Simrat
Role
EVP, Head of R&D
Sold
33,830 shs ($2.76M)
Approx. gross sale proceeds
$2.76M
Approx. exercise cost
$614K
Approx. pre-tax spread
$2.14M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 7,998 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 8,332 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,998 | $8.44 | $68K |
| Exercise | Common Stock | 5,000 | $17.88 | $89K |
| Exercise | Common Stock | 8,332 | $21.77 | $181K |
| Exercise | Common Stock | 12,500 | $22.07 | $276K |
| Sale | Common Stock | 33,830 | $81.48 | $2.76M |
Holdings After Transaction:
Stock Option (Right to Buy) — 235,606 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (5)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
- F2. The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F3. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F4. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F5. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Simrat Randhawa report for Dianthus Therapeutics (DNTH)?
Simrat Randhawa reported exercising stock options covering 33,830 Dianthus Therapeutics shares and selling 33,830 common shares. These transactions reflect an exercise-and-sell pattern, where options are converted into stock and then fully sold in the market on the same date.
Were Simrat Randhawa’s DNTH stock transactions under a Rule 10b5-1 trading plan?
Yes. The filing states the reported transaction was effected under a Rule 10b5-1 trading plan adopted on August 14, 2025. Such plans pre-schedule trades, indicating the timing of this exercise-and-sale sequence was determined in advance rather than chosen opportunistically.
How many Dianthus Therapeutics (DNTH) options did Simrat Randhawa exercise?
Randhawa exercised stock options covering a total of 33,830 shares of Dianthus Therapeutics common stock. The options carried various exercise prices, including $8.44, $17.88, $21.77 and $22.07 per share, and were converted into common shares before being sold.
What was Simrat Randhawa’s direct DNTH common stock holding after these transactions?
After the reported transactions, Randhawa held zero shares of Dianthus Therapeutics common stock directly. The filing’s ownership table shows total shares of common stock following the open-market sale as 0, indicating the newly acquired shares from the option exercises were fully disposed.
What role does Simrat Randhawa hold at Dianthus Therapeutics (DNTH)?
Simrat Randhawa serves as Executive Vice President and Head of R&D at Dianthus Therapeutics. The position is disclosed in the insider report, which identifies Randhawa as an officer, providing context for the reported option exercises and subsequent sale of company shares.